Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic

NEW YORK, March 26, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Actavis plc Ordinary Shares (NYSE: ACT), Thermo Fisher Scientific Inc. (NYSE: TMO), and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Biogen  Idec  Inc.  Analyst  Notes

On March 21, 2014, Biogen Idec Inc. (Biogen Idec) announced that the first long-acting fully recombinant clotting factor therapy - ALPROLIX™, has been approved by Health Canada. According to Biogen Idec, ALPROLIX is the first approved long-acting hemophilia B therapy. It is also the first worldwide approval for the product, which is currently being reviewed by regulatory authorities in several other countries, including the United States, Australia and Japan. ALPROLIX™ is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic (protective) infusions starting at once weekly or once every 10-14 days. "Health Canada's approval of ALPROLIX marks the first significant treatment advance in hemophilia B in 17 years, and reinforces our commitment to developing innovative therapies that help address the critical needs of the hemophilia community," said George A. Scangos, Ph.D., CEO of Biogen Idec. "We believe that the safety, efficacy and prophylactic dosing schedule demonstrated with ALPROLIX will provide people with hemophilia B a meaningful new way to manage their condition." The full analyst notes on Biogen Idec Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03262014/BIIB/report.pdf

--

Alexion  Pharmaceuticals,  Inc.  Analyst  Notes

On March 21, 2014, shares of Alexion Pharmaceuticals, Inc. (Alexion) closed at $159.79, down 7.99% from its previous day's closing price. Over the past three trading sessions, Alexion's shares dived 11.68% while the Nasdaq Composite slipped only by 1.24% during the same period. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03262014/ALXN/report.pdf

--

Actavis  plc  Analyst  Notes

On March 21, 2014, Actavis plc (Actavis) announced that it will release its Q1 2014 financial results on Wednesday, April 30, 2014, prior to market hours. To discuss the results, a conference call will be hosted by the Company, which will be webcast at 8:30 a.m. ET on the same day. The live and the archived version of the webcast will be available at the Company's website. The full analyst notes on Actavis plc are available to download free of charge at:

http://www.AnalystsReview.com/03262014/ACT/report.pdf

--

Thermo  Fisher  Scientific  Inc.  Analyst  Notes

On March 21, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher) issued a press release stating that Instrument manufacturers, as well as QA/QC managers in pharmaceutical and electronics manufacturing now have a new tool at their disposal. The tool is a new series of dry reference beads designed for calibrating airborne particle counters (APC) that need to comply with ISO 21501-4 regulations. In order to accomplish this, Thermo Fisher reported that its 4D Series Duke Standards beads feature a calibration uncertainty - the range of values within which the actual mean diameter will lie - that is less than or equal to 2.5% of the mean diameter. The Company said that the diameter is traceable to the National Institute of Standards and Technology (NIST), and the product's Certificate of Calibration and Traceability provides the documentation needed for QC/regulatory programs and audits. The full analyst notes on Thermo Fisher Scientific Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03262014/TMO/report.pdf

--

Medtronic,  Inc.  Analyst  Notes

On March 21, 2014, Medtronic, Inc.'s (Medtronic) stock fell 1.26% to close at $58.83 per share. Shares of Medtronic also slipped 0.05% during the last five days of trading, while the S&P 500 gained 1.37% during that same period. The full analyst notes on Medtronic, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03262014/MDT/report.pdf

--

About  Analysts  Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR  NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review